Şirket yükleniyor
Editas Medicine, Inc.
EDIT · Nasdaq · ·
$2,13-%10,512 Kas kapanış
30 Eylül 2026 tarihine kadarki rakamlar, 9 Kasım 2026 tarihinde sunulan 10-Q raporundan
Geçmiş getiri
- 1W
- -%17,1
- 1M
- -%12,9
EDIT · Nasdaq · ·
$2,13-%10,512 Kas kapanış
30 Eylül 2026 tarihine kadarki rakamlar, 9 Kasım 2026 tarihinde sunulan 10-Q raporundan
Just reported
From Editas Medicine's results release of 9 Kasım 2026; its quarterly report has since been filed.
Actual
$10,4M
+%37 y/y
-%13 q/q
Guided
—
No guide given
Actual
-$0,15
Guided
—
No guide given
Actual
-$24,3M
Guided
—
No guide given
Set against the company's own guidance and the same quarter a year earlier, not analysts' estimates, which we do not hold. Adjusted figures are the company's own non-GAAP measures, as stated in the release.
The themes Editas Medicine is part of, the highest-graded companies in its industry, and the companies in its sector whose grade rose recently.
Graded A or B and worth $2B or more: A first, then the largest.
ONCBeone Medicines Ltd.$47,5BA+
EXELExelixis, Inc.$17BA+
JAZZJazz Pharmaceuticals plc$15,4BA
HALOHalozyme Therapeutics, Inc.$11,5BA+
TECHBIO-Techne Corp$11,4BA+Rose to A or B on a filing in the last 90 days, worth $2B or more: largest first.
DHRDanaher Corporation21 Eki 2026CBGraded C, now B
MCKMckesson Corporation4 Kas 2026BAGraded B, now A
CVSCVS Health Corp4 Kas 2026BAGraded B, now A
EWEdwards Lifesciences Corporation4 Kas 2026BAGraded B, now A
BIIBBiogen Inc.28 Eki 2026BAGraded B, now AGelir payları FY2025 dönemi için tahmindir; resmî bir bildirimden alınmış rakamlar değildir.
EDIT-401
An experimental one-time treatment designed to edit liver cells so they produce more of a protein that removes LDL cholesterol from the blood. It was being prepared for a Phase 1/2 human trial in people with inherited high cholesterol.
In-vivo blood stem-cell editing program
A research program intended to edit blood-forming stem cells inside the body to raise fetal hemoglobin, with the aim of treating sickle cell disease and transfusion-dependent beta thalassemia.
Cas9 and Cas12a gene-editing technology
Gene-editing tools that Editas licenses to partners for research and development of medicines, including treatments that modify immune cells.
Editas develops medicines that change deoxyribonucleic acid (DNA) to treat disease. Its CRISPR (clustered regularly interspaced short palindromic repeats) technology uses a guide molecule to direct an enzyme to a chosen DNA location. Its lead medicine, EDIT-401, is being prepared for early human testing to lower low-density lipoprotein (LDL) cholesterol; the company also licenses its technology and works with drug companies on research programs.
Editas Medicine, Inc. şirketinin ABD Menkul Kıymetler ve Borsa Komisyonu’na (SEC) sunduğu kendi belgelerinden kuruldu. Rakamlar bildirildiği gibidir; hisse başına geçmiş bugünkü hisse tabanına göre yeniden hesaplanmıştır. Bu bir işletmeyi anlatır — yatırım tavsiyesi değildir ve alma ya da satma önerisi değildir.
Editas Medicine licenses gene-editing technology to drug companies and develops experimental medicines for people with serious diseases.
Grade B-
Fiyatın altındaki şerit, her tarihteki notu gösterir; yalnızca o tarihe kadar yayımlanmış belgelerden hesaplanır.
Editas Medicine, Inc. şirketinin not geçmişinin 32 çeyreğinden 2 tanesi gösteriliyor. Diğer 30 çeyrek Mart 2019 tarihine kadar uzanıyor.